PMID- 20682597
OWN - NLM
STAT- MEDLINE
DCOM- 20120119
LR  - 20220224
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
VI  - 17
IP  - 5
DP  - 2011 Oct
TI  - Different effects of enoxaparin, nadroparin, and dalteparin on plasma TFPI during 
      hemodialysis: a prospective crossover randomized study.
PG  - 480-6
LID - 10.1177/1076029610376936 [doi]
AB  - BACKGROUND: Low-molecular-weight heparins (LMWHs) are an alternative to 
      unfractionated heparin (UFH) for anticoagulation during hemodialysis (HD). We 
      performed a prospective randomized crossover study of the effect of enoxaparin, 
      nadroparin, and dalteparin on some hemostatic factors, including tissue factor 
      pathway inhibitor (TFPI), in patients with maintenance HD. METHODS: Plasma levels 
      (immunoassays) of total TFPI, platelet-derived growth factor-AB (PDGF-AB), and 
      prothrombin fragment 1 + 2 (PF 1 + 2) were evaluated pre-HD, after 10 (T10) and 
      180 (T180) minutes of HD in 21 patients, who completed a 3-period (for 2 months 
      each) crossover study in 6 groups (Latin-square design). RESULTS: The baseline 
      TFPI, PDGF-AB, and PF 1 + 2 levels were comparable under all LMWH treatments. 
      Tissue factor pathway inhibitor levels, compared with the baseline, significantly 
      increased (all P < 10(-4)), whereas PDGF-AB levels remained stable at each 
      interval during enoxaparin, nadroparin, and dalteparin anticoagulated HD. 
      Interestingly, TFPI increment at T10 was the highest, dose-dependent, and 
      accompanied by PF 1 + 2 decrease under enoxaparin administration. CONCLUSION: The 
      switch from enoxaparin to nadroparin and dalteparin used as anticoagulants had no 
      long-term effect on the baseline total TFPI and PF 1 + 2 levels in chronically HD 
      patients. Only short-term, overdialytic differences were noticed, indicating a 
      single bolus of enoxaparin (0.75 mg/kg) as the most potent stimulus for 
      endothelial TFPI.
FAU - Naumnik, Beata
AU  - Naumnik B
AD  - Department of Nephrology and Transplantation with Dialysis Unit, Medical 
      University, Bialystok, Poland. bnaumnik@poczta.onet.pl
FAU - Rydzewska-Rosolowska, Alicja
AU  - Rydzewska-Rosolowska A
FAU - Mysliwiec, Michal
AU  - Mysliwiec M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20100803
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Enoxaparin)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Lipoproteins)
RN  - 0 (Nadroparin)
RN  - 0 (Peptide Fragments)
RN  - 0 (Platelet-Derived Growth Factor)
RN  - 0 (lipoprotein-associated coagulation inhibitor)
RN  - 0 (platelet-derived growth factor AB)
RN  - 0 (prothrombin fragment 1.2)
RN  - 9001-26-7 (Prothrombin)
RN  - S79O08V79F (Dalteparin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cross-Over Studies
MH  - Dalteparin/*administration & dosage/adverse effects
MH  - Enoxaparin/*administration & dosage/adverse effects
MH  - Female
MH  - Fibrinolytic Agents/*administration & dosage/adverse effects
MH  - Humans
MH  - Lipoproteins/*blood
MH  - Male
MH  - Middle Aged
MH  - Nadroparin/*administration & dosage/adverse effects
MH  - Peptide Fragments/blood
MH  - Platelet-Derived Growth Factor/metabolism
MH  - Prospective Studies
MH  - Prothrombin
MH  - *Renal Dialysis
EDAT- 2010/08/05 06:00
MHDA- 2012/01/20 06:00
CRDT- 2010/08/05 06:00
PHST- 2010/08/05 06:00 [entrez]
PHST- 2010/08/05 06:00 [pubmed]
PHST- 2012/01/20 06:00 [medline]
AID - 1076029610376936 [pii]
AID - 10.1177/1076029610376936 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2011 Oct;17(5):480-6. doi: 10.1177/1076029610376936. 
      Epub 2010 Aug 3.